Nexstim Receives an NBS System Order from a Customer in Europe

Press release, Helsinki, 19 August 2022 at 10 AM (EEST)


Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an order for NBS 5 system from a customer in Europe. The customer is an experienced user of the Nexstim NBS system, now acquiring a new system to replace their old system and to enable future neuroscience projects.

Nexstim’s SmartFocus® nTMS (navigated transcranial magnetic stimulation) technology enables accurate and personalized stimulation, considering the unique shape and conductivity of each patient’s brain. Nexstim’s NBS (Navigated Brain Stimulation) system is used, for example, in planning neurosurgery and in the case of this customer enables neuroscience studies where the stimulation needs to be targeted individually to the brain, reproducing the pulse delivery reliably for diagnosis.

This specific NBS system also includes the software of an NBT® (Navigated Brain Therapy) system, allowing it to also be used for the treatment of major depression and chronic neuropathic pain.

Mikko Karvinen, CEO of Nexstim, comments: “TAt Nexstim, our values are solidly grounded in science, and we are committed to using our technological know-how to create world-leading products for neurosurgical planning, multiple therapies, and research. With our products such as the combined diagnostics and therapy system option, we aim to facilitate future innovation in the leading research hospitals and centers of the world. This order once again demonstrates the huge potential there is in using Nexstim systems for research purposes.


Further information is available on the website, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit